Anavex Life Sciences (FRA:12X1) 3-Year Book Growth Rate : 57.90% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences 3-Year Book Growth Rate?

Anavex Life Sciences's Book Value per Share for the quarter that ended in Dec. 2023 was €1.52.

During the past 12 months, Anavex Life Sciences's average Book Value per Share Growth Rate was -4.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was 57.90% per year. During the past 5 years, the average Book Value per Share Growth Rate was 43.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Anavex Life Sciences was 227.10% per year. The lowest was -528.30% per year. And the median was 20.10% per year.

Competitive Comparison of Anavex Life Sciences's 3-Year Book Growth Rate

For the Biotechnology subindustry, Anavex Life Sciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anavex Life Sciences's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's 3-Year Book Growth Rate falls into.

Anavex Life Sciences 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Anavex Life Sciences (FRA:12X1) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Anavex Life Sciences 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences (FRA:12X1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (FRA:12X1) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

AVXL:USA

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (FRA:12X1) Headlines

No Headlines